{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:47:04Z","timestamp":1777909624882,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T00:00:00Z","timestamp":1259020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2009,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We studied the effect of an intracameral bevacizumab injection on the corneal endothelium and iris neovessels (INV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Ten eyes were studied in 10 patients with an average age of 52.1 \u00b1 13.17 years. Patients underwent intracameral bevacizumab injections at a concentration of 1.25 mg\/0.05 mL. Intraocular pressure, best-corrected visual acuity, gonioscopy, neovascular membrane extent, anterior segment photography, iris fluorescein angiography, pachymetry, and specular microscopy were recorded preoperatively and postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The minimum follow-up period was 4 months. INVs started to regress within the first 2 days after the injection and regressed completely by the end of the fourth week. Reduction in INV leakage started 1 week after injection, and resolved in 8 eyes (80%) by the end of the fourth week. Intraocular pressure dropped significantly from 17.8 \u00b1 4.8 mmHg to 16.6 \u00b1 2.8 mmHg over 4 weeks. The mean endothelial cell loss was 3.95% \u00b1 6.78%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>An intracameral bevacizumab injection proved to be safe for corneal endothelial cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2009.0056","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T09:12:09Z","timestamp":1259053929000},"page":"513-518","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Intracameral Bevacizumab Injection on Corneal Endothelial Cells: An\n                    <i>In Vivo<\/i>\n                    Evaluation"],"prefix":"10.1177","volume":"25","author":[{"given":"Mohamed H.","family":"Hosny","sequence":"first","affiliation":[{"name":"Ophthalmology Clinic, Faculty of Medicine, Cairo University, Giza, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Zayed","sequence":"additional","affiliation":[{"name":"Ophthalmology Clinic, Faculty of Medicine, Cairo University, Giza, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad M.M.","family":"Shalaby","sequence":"additional","affiliation":[{"name":"Ophthalmology Clinic, Faculty of Medicine, Cairo University, Giza, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman M.","family":"Eissa","sequence":"additional","affiliation":[{"name":"Ophthalmology Clinic, Faculty of Medicine, Cairo University, Giza, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,11,24]]},"reference":[{"key":"e_1_3_1_2_2","first-page":"1929","article-title":"Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor","volume":"37","author":"Kvanta A.","year":"1996","unstructured":"Kvanta A., , Algvere P.V., , Berglin L., et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37:1929\u20131934, 1996.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_1_3_2","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization","volume":"39","author":"Amano S.","year":"1998","unstructured":"Amano S., , Rohan R., , Kuroki M., et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 39 :. 18\u201322 ,, 1998.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate","volume":"114","author":"Adamis A.P.","year":"1996","unstructured":"Adamis A.P., , Shima D.T., , Tolentino M., et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. . Arch Ophthalmol. 114:66\u201371, 1996.","journal-title":". Arch Ophthalmol"},{"key":"e_1_3_1_5_2","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis","volume":"146","author":"Dvorak H.F.","year":"1995","unstructured":"Dvorak H.F., , Brown L.F., , Detmar M., et al. Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029\u20131039, 1995.","journal-title":"Am. J. Pathol"},{"key":"e_1_3_1_6_2","first-page":"3974","article-title":"Mechanisms of retinal and choroidal neovascularization","volume":"35","author":"D\u2019Amore P.A","year":"1994","unstructured":"D\u2019Amore P.A. Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 35:3974\u20133979, 1994.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_1_7_2","article-title":"Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration","volume":"20","author":"Ciulla T.A.","year":"2009","unstructured":"Ciulla T.A., , and Rosenfeld P.J. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr. Opin. Ophthalmol. 20 :166\u2013174, 2009.","journal-title":"Curr. Opin. Ophthalmol"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":"The Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis","volume":"142","author":"Grisanti S.","year":"2006","unstructured":"Grisanti S., , Biester S., , Peters S., , et al. The Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am. J. Ophthalmol. 142:158\u2013160, 2006.","journal-title":"Am. J. Ophthalmol"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/IJG.0b013e318170a747","article-title":"Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients","volume":"18","author":"Duch S.","year":"2009","unstructured":"Duch S., , Buchacra O., , Milla E., et al. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J. Glaucoma. 18:140\u2013143, 2009.","journal-title":"J. Glaucoma"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.132"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/01.cco.0000183672.15133.ab","article-title":"Update on angiogenesis inhibitors","volume":"17","author":"Zakarija A.","year":"2005","unstructured":"Zakarija A., , and Soff G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 17:578\u2013583, 2005.","journal-title":"Curr. Opin. Oncol"},{"key":"e_1_3_1_12_2","first-page":"353","article-title":"Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration","volume":"40","author":"Ng E.W.M.","year":"2005","unstructured":"Ng E.W.M., , and Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 40:353\u2013368, 2005.","journal-title":"Can. J. Ophthalmol"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(81)34900-8"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(84)34292-0"},{"key":"e_1_3_1_15_2","first-page":"137","article-title":"The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases","volume":"68","author":"Michaelson I.C","year":"1948","unstructured":"Michaelson I.C. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans. Ophthalmol. Soc. U.K. 68:137\u2013180, 1948.","journal-title":"Trans. Ophthalmol. Soc. U.K"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00775-8"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":":232","DOI":"10.1016\/S0161-6420(98)92782-8","article-title":"Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma","volume":"105","author":"Tripathi R.C.","year":"2001","unstructured":"Tripathi R.C., , Li J., , Tripathi B.J., , et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 105::232\u2013237, 2001.","journal-title":"Ophthalmology"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Gregori N.Z. Gaitan J. Rosenfeld P.J. et al. . Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina. 28:1325\u20131337 2008.","DOI":"10.1097\/IAE.0b013e318188501f"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.064"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.066"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","DOI":"10.1136\/bjo.2008.145714","article-title":"Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma","volume":"93","author":"Grover S.","year":"2009","unstructured":"Grover S., , Gupta S., , Sharma R., et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br. J. Ophthalmol. 93 :273\u2013274, 2009.","journal-title":"Br. J. Ophthalmol"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","DOI":"10.1177\/112067210801800214","article-title":"Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma","volume":"18","author":"Chalam K.V.","year":"2008","unstructured":"Chalam K.V., , Gupta S.K., , Grover S., et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur. J. Ophthalmol. 18 :255\u2013262, 2008.","journal-title":"Eur. J. Ophthalmol"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318180e572"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1442-9071.2007.01521.x","article-title":"Bevacizumab (Avastin) for the treatment of neovascular glaucoma","volume":"35","author":"Chilov M.N.","year":"2007","unstructured":"Chilov M.N., , Grigg J.R., , and Playfair T.J. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin. Experiment. Ophthalmol. 35:494\u2013496, 2007.","journal-title":"Clin. Experiment. Ophthalmol"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(01)01018-5"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2008.12.017"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181659e56"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2008.01683.x"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2009.0056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2009.0056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2009.0056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:35:39Z","timestamp":1777646139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2009.0056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,24]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12,1]]}},"alternative-id":["10.1089\/jop.2009.0056"],"URL":"https:\/\/doi.org\/10.1089\/jop.2009.0056","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,24]]}}}